GCG and metabolic dysfunction-associated steatotic liver disease: Anticipated to improve glycemic control (via incretin release) and reduce NAFLD activity (less steatosis, inflammation, and fibrosis) based on animal models. Human trials are in early phases; efficacy in T2D/NAFLD remains to be confirmed.